Medtech Funding Trends Tracker

Medtech Funding Trends Tracker is your one post stop to understand all that is happening in medtech funding arena. News source: Fierce Biotech, Profile Source: Social Media Platform

It captures basic company details and other associated data for readers across globe, enabling them to get overall picture of Medtech funding activities.



GC Aesthetics

Welcome to GC Aesthetics, specialists in premium aesthetic supplies. Our implant brands include Nagor, the only British manufacturer of high quality silicone implants and Eurosilicone, innovative developer and producer of field-leading breast, facial and body implants and tissue expanders. Collectively, our brands have nearly 60 years of experience which has been used to improve the way our products fit beautifully with our physicians’ and patients’ needs.

SpecialtiesMedical Devices, Reconstruction Products, Breast Implants, Augmentation Products, Medical Aesthetics, Silicone Implants, Nagor implants, Eurosilicone Implants, Breast Augmentation, Cosmetic Surgery Devices, Plastic Surgery Devices, Scar Therapy

Websitehttp://www.gcaesthetics.com/

IndustryMedical Devices

TypePrivately Held

HeadquartersSuite 601, Q House, Furze Road Sandyford, Dublin 18 Ireland

GC Aesthetics reels in $20M Series D (Recent news release)


Augmenix, Inc

Augmenix, Inc. is a privately held medical device company focused on the development and commercialization of radiation oncology and urology products using its proprietary hydrogel technology. The company is using this technology to develop products that decrease unintended radiation damage to normal organs during cancer radiation therapy and to mark soft tissue. The SpaceOAR System (OAR stands for “organ at risk”) is an absorbable hydrogel that temporarily moves the rectum away from the prostate and the high intensity radiation zone, protecting the rectum in men undergoing radiation therapy for prostate cancer. Clinically proven, the created space reduces rectal radiation injury and the resulting long term complications. It is the first and only prostate cancer spacing device to receive Food and Drug Administration (FDA) clearance. Additionally, Augmenix has developed an absorbable tissue marker that marks soft tissue for a surgical procedure or future surgical procedures. TraceIT Tissue Marker is visible on multi-modality imaging allowing for improved tissue marking. This technology, licensed from Incept, LLC, comes from a line of products that have made a meaningful impact in the areas of neurosurgery and interventional cardiology. Augmenix is bringing this technology to the field of radiation oncology through high quality investors and an experienced management team. Augmenix, SpaceOAR, and SpaceOAR logo are registered trademarks of Augmenix, Inc.

Websitehttp://www.augmenix.com

IndustryMedical Devices

TypePrivately Held

Headquarters204 Second Ave. Augmenix Inc Waltham, Massachusetts 02451 United States

Company Size11-50 employees

Founded2008

Company Size201-500 employees$6M

Series E to boost next-gen versions of protective injectable hydrogel for Augmenix (Recent News Release)


Endotronix

A privately held, development stage medical device company engaged in the field of wireless health monitoring. Endotronix has developed a next-generation technology for measuring blood pressure in key areas of the human circulatory system using tiny implanted sensors and a small, handheld reader device.

Websitehttp://www.endotronix.com

IndustryMedical Devices

TypePrivately Held

Company Size11-50 employees

Founded2007

Endotronix raises $32M Series C for heart failure management


Mazor Robotics

At Mazor Robotics, we believe in healing through innovation by developing and introducing revolutionary robotic-based technology and products aimed at redefining the gold standard of quality care. Renaissance®, Mazor Robotics’ mechanical guidance system, is transforming spine surgery from freehand to state-of-the-art procedures that raise the standard of care with improved patient outcomes. Mazor means healing, or cure, in Hebrew, and our number one mission is to help heal patients in need. We strive for this mission each day by leading and innovating global spine and brain surgery with our one-of-a-kind Renaissance® Guidance System and complementary products. Furthermore, we are elevating the art of spine and brain surgery from typical freehand procedures to leading-edge, effective, state-of-the-art procedures, to define the future of surgical technology – today. Mazor Robotics’ flagship product, the Renaissance Guidance System, combines 3D planning, mechanical guidance, and 1.5mm accuracy to provide surgeons with a better solution for: minimally-invasive and percutaneous fusions, complex spinal deformity correction, trauma cases, and cranial procedures.

Specialties robotics, guidance, spinal surgery, 3D imaging, spinal implants, medical devices

Websitehttp://www.MazorRobotics.com

IndustryMedical Devices

TypePublic Company

HeadquartersPO Box 3104 38900 Caesarea Industrial Park Cesarea, Israel 38900 Israel

Company Size51-200 employees

Founded2001

Recent News:Mazor picks up $20M from Medtronic, launches spine surgery robot


Profusa

Profusa’s mission is to make our body’s chemistry easily accessible to improve health and wellness. We are dedicated to becoming a leader in the development of real-time biosensors that provide unprecedented insights into our overall health status. We are leading the development of a new generation of biointegrated sensors that empowers the individual with the ability to monitor their unique body chemistry in unprecedented ways to transform the management of personal health and disease. Our technology enables the development of bioengineered sensors that become one with the body to detect and continuously transmit actionable, medical-grade data for personal and medical use. Profusa’s first clinical offering, the Lumee Oxygen Sensing System™, is designed to report reliable tissue oxygen levels at various regions of interest, both acutely and long-term. It may be used in applications where monitoring of compromised tissue is beneficial, such as peripheral artery disease that results in narrowing of blood vessels and reduced blood flow to the lower limbs; chronic wounds (diabetic ulcers, pressure sores) that do not heal properly; and reconstructive surgery. Any questions? Please visit profusa.com or email us at info@profusa.com

Website http://www.profusa.com

Industry Medical Devices

Type Privately Held

Headquarters 345 Allerton Ave South San Francisco, California 94080 United States

Company Size 11-50 employees

Founded 2009

Recent News Release:Profusa wins $7.5M from DARPA for biosensor implants


Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s